Lung Cancer Non-small Cell Stage IV Clinical Trial
Official title:
Osimertinib as First Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer: the Experience of the Hellenic Cooperative Oncology Group (HeCOG)
The present study will evaluate the use of osimertinib as 1st line therapy for patients with advanced EGFR positive non-small cell lung cancer who are treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology.
This will be an observational, multicentric, retrospective/ prospective analysis of patients with advanced EGFR positive non-small cell lung cancer that receive osimertinib as 1st line therapy. The patient data will be collected at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology during scheduled patient clinical visits, from February 2020 for a total period of three years. The biological material obtained from the patients of this analysis will be possibly used in a future translational study as an exploratory analysis. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03866980 -
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT03692442 -
Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform
|
||
| Recruiting |
NCT03769103 -
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
|
Phase 2 | |
| Completed |
NCT02129699 -
Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy
|
Phase 3 | |
| Completed |
NCT03866993 -
A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT04184921 -
Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients
|